Investigation
Kewaunee Scientific Corporation (KEQU)
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Menu
Investigation
06/21/2021
Initial Lawsuit
06/21/2021
Lawsuit Progression
09/10/2021
This is a federal securities class action on behalf of all persons and entities other than Defendants that purchased or admin otherwise acquired Home Point common stock pursuant and/or traceable to the Company’s January 29, 2021, initial public offering.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) Home Point’s aggressive expansion of its broker partners would dramatically increase the Company’s expenses;
(ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures;
(iii) accordingly, the Company had overstated its business and financial prospects;
(iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.